PD-L1 Expression and Silva Invasion Pattern in Villoglandular Adenocarcinoma of the Uterine Cervix.
Journal
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
ISSN: 1538-7151
Titre abrégé: Int J Gynecol Pathol
Pays: United States
ID NLM: 8214845
Informations de publication
Date de publication:
31 Jan 2024
31 Jan 2024
Historique:
medline:
31
1
2024
pubmed:
31
1
2024
entrez:
31
1
2024
Statut:
aheadofprint
Résumé
Villoglandular adenocarcinoma (VGA) of the uterine cervix is a rare subtype of endocervical adenocarcinoma in young women. Between 2007 and 2020, all women with endocervical adenocarcinoma were retrospectively reviewed to find patients with VGA. Eight patients in whom pure VGA had been diagnosed were included. The mean age at initial diagnosis was 36.3 years (range 24-46). After surgical treatment, patients were followed up for 59 months (range 16-150). To date, all patients are alive with no evidence of disease. Neither lymph node involvement nor lymphovascular invasion was found. Furthermore, we examined the samples with a focus on morphological invasion pattern (Silva), stromal tumor-infiltrating lymphocytes (sTILs), and immunohistochemical programmed death ligand-1 (PD-L1) expression. PD-L1 expression was observed in 7/8 using the combined positive score (cutoff≥1%), 1/8 of VGAs using the tumor proportion score (cutoff≥1%), and 7/8 using the immune cell (cutoff≥1%). Using combined positive score and immune cell, PD-L1 expression was seen in 7/8 of pattern B and C tumors, with significantly higher expression in tumors with destructive-type patterns (P<0.05, A vs. B+C). Using tumor proportion score, no significant difference in PD-L1 expression was seen between VGAs with different invasion patterns. VGAs demonstrated twice higher sTILs in tumors with destructive-type invasion patterns. Our observations suggest that PD-L1 expression, tumor invasion patterns, and sTILs do not correlate with the excellent prognosis of pure VGA.
Identifiants
pubmed: 38293999
doi: 10.1097/PGP.0000000000001006
pii: 00004347-990000000-00135
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 by the International Society of Gynecological Pathologists.
Déclaration de conflit d'intérêts
A.H. has received honoraria for lectures or consulting/advisory boards for Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Illumina, Ipsen, Janssen, Lilly, MSD, NanoString, Novartis, Qiagen, QUIP GmbH, Roche, 3DHistotech. R.E. has received honoraria from Roche, Eisai, Pfizer, Mindpeak, AstraZeneca, and Novartis and travel grants from BioNTech. The institution of A.H. and R.E. conducts research for AstraZeneca, Roche, Janssen-Cilag, Zytomed Systems, NanoString Technologies, Veracyte, Biocartis, Novartis, Cepheid, and BioNTech. The remaining authors declare no conflict of interest.
Références
Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Prev Med 2019;123:316–23.
van der Horst J, Siebers AG, Bulten J, et al. Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. Cancer Med 2017;6:416–23.
Fujiwara K, Monk B, Devouassoux-Shisheboran M. Adenocarcinoma of the uterine cervix: why is it different? Curr Oncol Rep 2014;16:416.
Kurman RJ CM, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. WHO Classification of Tumours 2014;6:169–89.
Young RH, Scully RE. Villoglandular papillary adenocarcinoma of the uterine cervix. A clinicopathologic analysis of 13 cases. Cancer 1989;63:1773–9.
Guo P, Liu P, Yang J, et al. Villoglandular adenocarcinoma of cervix: pathologic features, clinical management, and outcome. Cancer Manag Res 2018;10:3955–61.
Hodgson A, Olkhov-Mitsel E, Howitt BE, et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): Correlation with adverse clinicopathological features and patient outcome. J Clin Pathol 2019;72:347–53.
Dietl AK, Beckmann MW, Aumann K. Villoglandular adenocarcinoma of the uterine cervix: a systematic review and meta-analysis. Arch Gynecol Obstet 2021;304:317–27.
Höhn AK, Brambs CE, Hiller GGR, et al. 2020 WHO Classification of female genital tumors. Geburtshilfe Frauenheilkd 2021;81:1145–53.
Roma AA, Diaz De Vivar A, Park KJ, et al. Invasive endocervical adenocarcinoma: a new pattern-based classification system with important clinical significance. Am J Surg Pathol 2015;39:667–72.
Alvarado-Cabrero I, Parra-Herran C, Stolnicu S, et al. The Silva pattern-based classification for HPV-associated Invasive endocervical adenocarcinoma and the distinction between in situ and invasive adenocarcinoma: Relevant Issues and recommendations from the International Society of Gynecological Pathologists. Int J Gynecol Pathol 2021;40(suppl 1):S48–s65.
Stolnicu S, Brito MJ, Karpathiou G, et al. Villoglandular pattern in HPV-associated endocrvical adenocarcinoma is assciated with excellent prognosis: a reappraisal of 31 cases using IECC and Silva pattern classification. Int J Gynecol Pathol 2023;42:270–7.
Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 2019;145:129–35.
Kluger HM, Zito CR, Turcu G, et al. PD-L1 Studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors. Clin Cancer Res 2017;23:4270–9.
Heeren AM, Punt S, Bleeker MC, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol 2016;29:753–63.
Reddy OL, Shintaku PI, Moatamed NA. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol 2017;12:45.
Rotman J, den Otter LAS, Bleeker MCG, et al. PD-L1 and PD-L2 Expression in cervical cancer: Regulation and biomarker potential. Front Immunol 2020;11:596825.
Rivera-Colon G, Chen H, Molberg K, et al. PD-L1 expression in endocervical adenocarcinoma: correlation with patterns of tumor invasion, CD8+ tumor-infiltrating lymphocytes, and clinical outcomes. Am J Surg Pathol 2021;45:742–52.
Omenai SA, Ajani MA, Okolo CA. Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients. PLoS One 2022;17:e0263615.
Zhou F, Chen H, Li M, et al. The prognostic values of HPV genotypes and tumor PD-L1 expression in patients with HPV-associated endocervical adenocarcinoma. Am J Surg Pathol 2022;46:300–8.
Diaz De Vivar A, Roma AA, Park KJ, et al. Invasive endocervical adenocarcinoma: proposal for a new pattern-based classification system with significant clinical implications: a multi-institutional study. Int J Gynecol Pathol 2013;32:592–601.
Erber R, Hartmann A. Understanding PD-L1 testing in breast cancer: a practical approach. Breast Care (Basel) 2020;15:481–90.
Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of Atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 2019;5:74–82.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540–50.
Kulangara K, Hanks DA, Waldroup S, et al. Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx. J Clin Oncol 2017;35(15_suppl):e14589–e14589.
Eckstein M, Cimadamore A, Hartmann A, et al. PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med 2019;7:690.
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol 2015;26:259–71.
Chen JH, Duan H, Yu XB, et al. Clinical features and prognostic factors of cervical villoglandular adenocarcinoma. Int J Gynecol Cancer 2021;31:512–7.
Jones MW, Silverberg SG, Kurman RJ. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: a clinicopathological study of 24 cases. Int J Gynecol Pathol 1993;12:1–7.
Dietl A, Klar M, Aumann K. Minimally invasive surgery for early-stage cervical cancer: Is the uterine manipulator a risk factor? Am J Obstet Gynecol 2019;221:537–8.
Zhang Y, Wang Y, Liu Y, et al. A retrospective study and literature review of cervical villoglandular adenocarcinoma: a candidate paradigm of Silva System Pattern A. Appl Immunohistochem Mol Morphol 2020;29:467–472.
Stolnicu S, Barsan I, Hoang L, et al. Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV. Gynecol Oncol 2018;150:56–60.
Stolnicu S, Hoang L, Almadani N, et al. Clinical correlation of lymphovascular invasion and Silva pattern of invasion in early-stage endocervical adenocarcinoma: Proposed binary Silva classification system. Pathology 2022;54:548–54.
Litwin TR, Irvin SR, Chornock RL, et al. Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. Br J Cancer 2021;124:831–41.
Punt S, van Vliet ME, Spaans VM, et al. FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. Cancer Immunol Immunother 2015;64:745–53.
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–71.
Mezache L, Paniccia B, Nyinawabera A, et al. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol 2015;28:1594–602.